Head-to-head

Tesamorelin vs MOTS-c

A field-by-field comparison of Tesamorelin and MOTS-c drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — growth hormone and metabolic — so this page focuses on what each one actually does rather than which is "better".

Tesamorelin vs MOTS-c at a glance

Attribute	Tesamorelin	MOTS-c
Category	Growth hormone	Metabolic
Evidence grade	Strong	Emerging
Also known as	Egrifta, TH9507	Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1-encoded peptide
Chain	44 amino acid stabilised GHRH analogue	16 amino acid mitochondrial-derived peptide
Mechanism	A stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1.	Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.
Reported benefits	Clinically demonstrated visceral adipose tissue reduction (~15–18%) · Improved triglycerides in trial populations · Preliminary evidence for cognitive benefit in older adults	Improved insulin sensitivity and glucose disposal in rodent models · Enhanced fat oxidation and reduced fat accumulation · Exercise-mimetic effects on metabolism and physical capacity · Potential protection against diet-induced metabolic dysfunction
Reported side effects	Joint pain and swelling · Injection-site erythema · Insulin resistance · Peripheral oedema	Limited human safety data · Injection-site irritation · Possible hypoglycaemia in susceptible individuals
Half-life	26–38 minutes	Estimated minutes to a few hours
Administration	Daily subcutaneous injection, abdomen	Subcutaneous injection; oral capsules are marketed but less validated
Dosing overview	Approved label dose is 2 mg once daily	Commonly cited at 5–10 mg daily, often for 4–12 week cycles
Storage	Refrigerated; reconstitute immediately before use per label	Lyophilised powder refrigerated; reconstituted vials 2–8 °C and used within ~30 days
Legal status	FDA-approved for a specific indication; other uses are off-label.	Research chemical; not approved as a drug.

Key differences between Tesamorelin and MOTS-c

Different categories, different goals

Tesamorelin is indexed under growth hormone, while MOTS-c sits under metabolic. They are not substitutes for one another: Tesamorelin is described as "The one GH-axis peptide with full FDA approval, indicated for reducing excess visceral abdominal fat in HIV-associated lipodystrophy." and MOTS-c as "A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects."

Mechanism of action

Tesamorelin: A stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1. MOTS-c: Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.

Evidence quality is not equal

Tesamorelin carries a Strong evidence grade and MOTS-c a Emerging grade on this index. The grade describes the quality of published human data, not how well a compound works — Tesamorelin has the better-documented record of the two, and claims made about MOTS-c rest on thinner human evidence.

Half-life and dosing frequency

Tesamorelin is listed at 26–38 minutes; MOTS-c at estimated minutes to a few hours. That difference is what drives the reported schedules: Approved label dose is 2 mg once daily versus Commonly cited at 5–10 mg daily, often for 4–12 week cycles

Route of administration

Tesamorelin is administered by daily subcutaneous injection, abdomen. MOTS-c is administered by subcutaneous injection; oral capsules are marketed but less validated.

Legal and regulatory status differs

Tesamorelin: FDA-approved for a specific indication; other uses are off-label. MOTS-c: Research chemical; not approved as a drug. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

Tesamorelin is stored refrigerated; reconstitute immediately before use per label. MOTS-c is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c and used within ~30 days.

What Tesamorelin and MOTS-c have in common

On the attributes tracked in this database — category, evidence grade, mechanism, half-life, administration, dosing overview, storage and legal status — Tesamorelin and MOTS-c share no identical values. They are compared here because they come up together in the same searches, not because they overlap.

Each compound in brief

Tesamorelin

Growth hormone · Strong evidence

The one GH-axis peptide with full FDA approval, indicated for reducing excess visceral abdominal fat in HIV-associated lipodystrophy.

Considerations: Visceral fat returns after discontinuation · Requires monitoring of fasting glucose and IGF-1 · Expensive relative to other GH secretagogues

MOTS-c

Metabolic · Emerging evidence

A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects.

Considerations: Most evidence is preclinical; human trials are small and early-phase · Short half-life may require daily or twice-daily dosing · Bioavailability of oral forms is uncertain compared with injection

Tesamorelin vs MOTS-c